Trk receptor
Trk receptor inhibitors target the Tropomyosin receptor kinases (Trk), a family of receptor tyrosine kinases that play a significant role in the development and function of the nervous system. Trk receptors are involved in neurotrophin signaling, which is essential for the survival, differentiation, and growth of neurons. Dysregulation of Trk signaling is associated with neurological disorders and certain cancers. At CymitQuimica, we offer Trk receptor inhibitors to support your research in neurobiology, oncology, and neurodegenerative diseases.
Found 59 products of "Trk receptor"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Amitriptyline hydrochloride
CAS:<p>Amitriptyline hydrochloride (Annoyltin) is the hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive</p>Formula:C20H24ClNPurity:97% - 99.94%Color and Shape:Crystals White To Off-White PowderMolecular weight:313.86CE-245677
CAS:<p>CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.</p>Formula:C24H22Cl2N6O3Purity:98.99% - 99.23%Color and Shape:SolidMolecular weight:513.38N-Acetyl-5-hydroxytryptamine
CAS:<p>N-Acetyl-5-hydroxytryptamine, or Normelatonin, is melatonin's precursor, made from serotonin, and activates TrkB receptor.</p>Formula:C12H14N2O2Purity:98.31% - 99.91%Color and Shape:SolidMolecular weight:218.25CRB-0089
<p>CRB-0089 is a human monoclonal antibody targeting NGF/bNGF. It is used in the study of analgesia.</p>Color and Shape:Odour LiquidAnti-TrkB/NTRK2 Antibody
<p>Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.</p>Color and Shape:Odour LiquidAdimanebart
CAS:<p>Amdokitug is a human-derived IgG1λ monoclonal antibody that acts as an inhibitor of MUSK.</p>Color and Shape:LiquidTrkA-IN-6
<p>TrkA-IN-6 (compound R48) is a hydrazone-based, selective inhibitor of the tropomyosin receptor kinase A (TrkA). It exhibits greater cytotoxicity towards U87 GBM cells compared to Temozolomide, with an IC50 of 68.99 μM.</p>Formula:C16H13N3O5Molecular weight:327.08552GNF-8625 monopyridin-N-piperazine hydrochloride
CAS:<p>GNF-8625 monopyridin-N-piperazine hydrochloride is a protomyosin receptor kinase (TRK) inhibitor.</p>Formula:C25H27ClFN7Purity:98.97%Color and Shape:SolidMolecular weight:479.98Protein kinase inhibitor 5 sulfate hydrate
<p>Protein kinase inhibitor 5 sulfate hydrate, a potent TRK-A inhibitor, exhibits an IC50 of 1.8 nM and impairs cell viability [1].</p>Formula:C29H35F2N7O6SPurity:98%Color and Shape:SolidMolecular weight:647.69PF-06737007
CAS:<p>PF-06737007 is an effective inhibitor of pan-Trk in cell-based assays (IC50s: 7.7 nM, 15 nM, and 3.9 nM for TrkA, TrkB, and TrkC, respectively).</p>Formula:C25H28F4N2O6Purity:98%Color and Shape:SolidMolecular weight:528.49Selitrectinib
CAS:<p>Selitrectinib (LOXO-195) is a potent and selective inhibitor of the receptor tyrosine kinases(TRK).Cost-effective and quality-assured.</p>Formula:C20H21FN6OPurity:99.55% - ≥95%Color and Shape:SolidMolecular weight:380.42ONO-7475
CAS:<p>ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase</p>Formula:C32H26N4O6Purity:98.74%Color and Shape:SolidMolecular weight:562.57Entrectinib
CAS:<p>Entrectinib (RXDX-101) is an orally Trk, ROS1, and ALK inhibitor. Entrectinib exhibits antitumor activity. Cost-effective and quality-assured.</p>Formula:C31H34F2N6O2Purity:98.03% - 99.61%Color and Shape:SolidMolecular weight:560.64Milciclib
CAS:<p>Milciclib (PHA-848125) is a potent CDK2 inhibitor with a 45 nM IC50, selective over CDK1/2/4/5/7. In Phase 2 trials.</p>Formula:C25H32N8OPurity:99.28%Color and Shape:SolidMolecular weight:460.57LM22A-4
CAS:<p>LM22A-4: BDNF mimetic, TrkB agonist, IC50=47 nM (fluorescence anisotropy).</p>Formula:C15H21N3O6Purity:99.56%Color and Shape:SolidMolecular weight:339.34Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.46Ensartinib hydrochloride
CAS:<p>Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known</p>Formula:C26H29Cl4FN6O3Purity:98.73%Color and Shape:SolidMolecular weight:634.36Belizatinib
CAS:<p>Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.</p>Formula:C33H44FN5O3Purity:99.33% - 99.44%Color and Shape:SolidMolecular weight:577.73ANA-12
CAS:<p>ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice.</p>Formula:C22H21N3O3SPurity:99.28% - 99.87%Color and Shape:SolidMolecular weight:407.49LOXO-195
CAS:<p>(6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.</p>Formula:C20H21FN6OPurity:99.54%Color and Shape:SolidMolecular weight:380.42GNF-5837
CAS:<p>GNF-5837 is a specific, and orally bioavailable pan-TRK inhibitor for TrkA/TrkB (IC50: 8/12 nM).</p>Formula:C28H21F4N5O2Purity:97.26% - 98.08%Color and Shape:SolidMolecular weight:535.49DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Formula:C41H42FN5O7Purity:99.75%Color and Shape:SolidMolecular weight:735.8GW 441756
CAS:<p>GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.</p>Formula:C17H13N3OPurity:97.73% - 99.8%Color and Shape:SolidMolecular weight:275.3Tyrphostin AG 879
CAS:<p>Tyrphostin AG 879 (AG 879) effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.</p>Formula:C18H24N2OSPurity:99.05%Color and Shape:SolidMolecular weight:316.46Sitravatinib
CAS:<p>Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and</p>Formula:C33H29F2N5O4SPurity:98.9% - 99.85%Color and Shape:SolidMolecular weight:629.68LM22B-10
CAS:<p>LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.</p>Formula:C27H33ClN2O4Purity:98.18%Color and Shape:SolidMolecular weight:485.01Larotrectinib
CAS:<p>Larotrectinib (LOXO-101) is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).</p>Formula:C21H22F2N6O2Purity:99.15% - >99.99%Color and Shape:SolidMolecular weight:428.44CH7057288
CAS:<p>CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB and TRKC, respectively.</p>Formula:C32H31N3O5SPurity:99.92%Color and Shape:SolidMolecular weight:569.67Larotrectinib sulfate
CAS:<p>Larotrectinib sulfate (LOXO-101 sulfate) is an oral active and specific ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).</p>Formula:C21H22F2N6O2·H2O4SPurity:98.62% - 99.76%Color and Shape:SolidMolecular weight:526.51Repotrectinib
CAS:<p>Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.</p>Formula:C18H18FN5O2Purity:99.92% - >99.99%Color and Shape:SolidMolecular weight:355.377,8-Dihydroxyflavone
CAS:<p>7,8-Dihydroxyflavone (7,8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.</p>Formula:C15H10O4Purity:98.48% - 99.81%Color and Shape:SolidMolecular weight:254.24Frunevetmab
CAS:<p>Frunevetmab (NV-02) is a feline-adapted monoclonal antibody targeting NGF (nerve growth factor), with a Kd value of 20 pM. Feline osteoarthritis (OA).</p>Purity:95% - 95%Color and Shape:LiquidFasinumab
CAS:<p>Fasinumab (anti-NGF mAb) is in Phase III trials for acute sciatica & knee OA. It significantly improves pain & function vs. placebo.</p>Purity:95%Color and Shape:LiquidFulranumab
CAS:<p>Fulranumab (AMG-403) is a humanised monoclonal antibody targeting NGF, analgesic effects, and can be used for the study of chronic pain.</p>Purity:95%Color and Shape:LiquidTanezumab
CAS:<p>Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF，pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.</p>Purity:95%Color and Shape:LiquidBMS-754807
CAS:<p>BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.</p>Formula:C23H24FN9OPurity:99.69% - 99.94%Color and Shape:SolidMolecular weight:461.49Protein kinase inhibitor 5
CAS:<p>Protein kinase inhibitor 5 is a potent inhibitor of TRK-A, demonstrating an IC50 of 1.8 nM, and effectively suppresses cell viability [1].</p>Formula:C29H31F2N7OPurity:98%Color and Shape:SolidMolecular weight:531.6Tavilermide
CAS:<p>Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.</p>Formula:C24H32N6O11Purity:98.98%Color and Shape:SolidMolecular weight:580.54TrkA-IN-1
CAS:<p>TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) (IC50: 99 nM in a cell-based assay) with analgesic activity.</p>Formula:C25H20N4OPurity:98%Color and Shape:SolidMolecular weight:392.45Paltimatrectinib
CAS:<p>Paltimatrectinib (PBI-200) is a tyrosine kinase inhibitor with anticancer activity, and is used in the study of bladder, breast, and colorectal cancers.</p>Formula:C20H15F5N6Purity:99.96%Color and Shape:SolidMolecular weight:434.37CG 428
CAS:<p>CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM.</p>Formula:C43H43FN10O6Purity:99.83%Color and Shape:SolidMolecular weight:814.86Type II TRK inhibitor 1
CAS:<p>Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.</p>Formula:C35H33F3N8O3Purity:98%Color and Shape:SolidMolecular weight:670.68ENT-C225
CAS:<p>ENT-C225 is a potent TrkB neurotrophin receptor (TrkBR) activator with neuroprotective activity for the study of Alzheimer's disease and Parkinson's disease.</p>Formula:C26H40N4O5Purity:99.36% - 99.36%Color and Shape:SolidMolecular weight:488.62PF-06733804
CAS:<p>PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.</p>Formula:C20H19F5N4O4Purity:98%Color and Shape:SolidMolecular weight:474.38TRK-IN-24
CAS:<p>TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,</p>Formula:C39H45N7O3Purity:98%Color and Shape:SolidMolecular weight:659.82AZ-23
CAS:<p>AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.</p>Formula:C17H19ClFN7OPurity:99.4%Color and Shape:SolidMolecular weight:391.83TRK-IN-28
CAS:<p>TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].</p>Formula:C27H25F2N7Color and Shape:SolidMolecular weight:485.53TRK-IN-26
CAS:<p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>Formula:C30H22F2N6O4Color and Shape:SolidMolecular weight:568.53TrkA-IN-7
CAS:<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Formula:C16H13N3O3Color and Shape:SolidMolecular weight:295.293TrkA-IN-8
CAS:<p>TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.</p>Formula:C20H16N4Color and Shape:SolidMolecular weight:312.368TrkA-IN-9
CAS:<p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>Formula:C31H32N4O4Color and Shape:SolidMolecular weight:524.61PF-06273340
CAS:<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Formula:C23H22ClN7O3Purity:98% - 98.00%Color and Shape:SolidMolecular weight:479.92NMS-P626
CAS:<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>Formula:C28H35F2N7O4SColor and Shape:SolidMolecular weight:603.68BNN-20
CAS:<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Formula:C20H30O2Color and Shape:SolidMolecular weight:302.45TrkC-IN-1
CAS:<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Formula:C28H20BrN5O2Color and Shape:SolidMolecular weight:538.395ONO-7579
CAS:<p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>Formula:C24H18ClF3N6O4SColor and Shape:SolidMolecular weight:578.95HS-345
CAS:<p>HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.</p>Formula:C19H18N6O2SColor and Shape:SolidMolecular weight:394.45Trk-IN-4
CAS:<p>Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.</p>Formula:C24H23F4N5O4Purity:98.13%Color and Shape:SolidMolecular weight:521.46TrkB-IN-1
CAS:<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Formula:C19H16N2O6Purity:98%Color and Shape:SolidMolecular weight:368.34
